Special Issue

New Insights into Tumor Microenvironment and Drug Repurposing

Message from the Guest Editors

The treatment of cancer patients and antitumor drug investigation have caused great financial burden on healthcare systems and the whole of society. The tumor microenvironment is constituted of various specialized microenvironments including hypoxic niche, immune microenvironment, metabolism microenvironment, acidic niche, innervated niche, mechanical microenvironment, and even microbiota: each specialized microenvironment has a close crosstalk with one other. The tumor microenvironment and drug repurposing are becoming hot topics. Drug repurposing. also known as drug repositioning, has accelerated the process and greatly reduced the cost of drug development. Metformin and thalidomide are two such successful cases. We sincerely welcome researchers working in this field to submit original research articles or reviews including, but not limited to, repurposed drugs for cancer treatments, the current status of drug repurposing, and approaches to identify a repurposed drugs candidate targeting the tumor microenvironment to this Special Issue: New Insights into Tumor Microenvironment and Drug Repurposing.

Guest Editors

Prof. Dr. Weilin Jin

Institute of Cancer Neuroscience, Medical Frontier Innovation Research Center, The First Hospital of Lanzhou University, The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China

Dr. Mingzhu Jin School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Deadline for manuscript submissions

closed (31 March 2022)



Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



mdpi.com/si/77405

Molecules Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 molecules@mdpi.com

mdpi.com/journal/

molecules





Molecules

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



molecules



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).